echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Clinical data of KN046 combined with chemotherapy in the first-line treatment of pancreatic cancer

    Clinical data of KN046 combined with chemotherapy in the first-line treatment of pancreatic cancer

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 7, 2021, Corning Jereh Biopharmaceuticals (stock code: 9966.


    Pancreatic cancer is recognized as the "king of cancer" in the medical field.


    This phase II clinical study in China enrolled patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) confirmed by histology or cytology, with an ECOG PS of 0-1.


    As of January 15, 2021, a total of 17 patients were enrolled, the median age (range) was 56 (36-75) years, 9 patients had an ECOG PS score of 1, and 7 patients had liver metastases at baseline


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.